| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697731 | Clinical Oncology | 2017 | 9 Pages |
Abstract
Single 15 Gy HDR brachytherapy with EBRT has a low rate of late genitourinary and gastrointestinal toxicities. Late urinary morbidity may be minimised by limiting the dose to the urethra, particularly for patients with larger prostates.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
N. Shahid, A. Loblaw, H.T. Chung, P. Cheung, E. Szumacher, C. Danjoux, R. Sankreacha, L. Zhang, A. Deabreu, A. Mamedov, G. Morton,